Aurora Spine (ASG) Planet MicroCap Showcase: VEGAS 2025 summary

Business overview and market positioning

• Focuses exclusively on spine implants, covering cervical to lumbar and SI joints, with a philosophy of fitting implants to patient anatomy for better outcomes.

• Expanded from traditional spine surgery into the interventional and pain management markets, emphasizing minimally invasive procedures.

• Achieved significant adoption among ortho, neuro, and pain doctors, with key products ZIP and SiLO now accounting for over 40% of monthly revenues.

• Sales force includes over 14 direct reps and 40+ independent distributors, with ongoing expansion into new U.S. regions.

• Most sales are in the U.S., with growing presence in Canada, Mexico, Central and South America.

Financial performance and growth

• Recorded $4.8 million in Q3 2024 revenue, up 21% year-over-year, driven by strong ZIP and SiLO sales.

• Achieved first positive net income in Q3 2024 and five consecutive quarters of positive EBITDA.

• Targeting continued EBITDA positivity in 2024 and a breakout cash-positive year in 2025, with plans to move to NASDAQ in 2026.

• Gross margins are a key focus, with efforts to accelerate returns and improve profitability.

• All products are approved on DOD contracts and covered by major insurance carriers.

Product innovation and pipeline

• ZIP device enables screwless, minimally invasive lumbar procedures, reducing OR time by 36% and blood loss by 69%.

• SiLO and SiLO TFX address the SI joint market, growing from zero to over 40% of monthly sales, with over 56 reusable instrument sets in the field.

• DEXA technology allows intraoperative matching of implant density to patient bone quality, a unique offering not available from major competitors.

• Multicenter studies underway for DEXA, ZIP, SiLO, AERO, and facet systems, with new product launches planned through 2025.

• All products are now proprietary, with no third-party distribution.